- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03553368
Chest Imaging of Lung Nodule(s) Under High-frequency Non-invasive Ventilation (HF-NIV)
Imaging of chest disorders is mainly achieved by using computed tomography. This is especially the case for detection, morphologic assessment and followup of pulmonary nodules. A positron emission tomography (PET) /CT may be additionally required for lung nodule management in some conditions including a size greater than 8 mm with morphologic or growing characteristics suspicious of malignancy. Magnetic Resonance Imaging (MRI) represents however an interesting alternative diagnostic radiation-free method, in particular owing to the recent development of sequences dedicated to lung parenchyma analysis. A major limitation remains the control of respiratory artefacts.
High Frequency non-invasive ventilation, HF-NIV, has the potential to allow chest stabilization and is currently used in the department of radio-oncology at the Lausanne University Hospital. It has been recently applied to perform MRI and PET examinations at end inspiration during an "apnea " generated by the system. Continuous periods of respiratory stabilization of several minutes at end-inspiration are thus obtained, allowing prolonged MR and PET acquisitions with improvement of image quality as observed in our preliminary studies (Beigelman-Aubry et al., Prior et al.). Interestingly, the lung volume explored by using this ventilation technique is similar to that of CT studies, conversely to respiratory gated MR sequences which are currently performed at end-expiration, this potentially generating underevaluation of lung disorders especially at lung bases.
The present project aims to determine the impact of HF-NIV in the management of patients with pulmonary nodule(s). After a first step of optimization of acquisition parameters of HF-NIV-MR in healthy volunteers, the performances of MRI and PET/CT (when required) under this ventilation technique will be compared to the current method(s) of reference in cases of pulmonary nodule(s) (CT scan and PET when required) and histological data when available. All MRI and PET/CT (when required) acquisitions will be performed without the ventilation technique, as used in current practice, and with it.
The project was completed with an amendment to investigate MRI under continuous positive airway pressure (CPAP). The MR-CPAP combination will be evaluated with optimized parameters in healthy volunteers and compared to free-breathing acquisitions without any device.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Lausanne, Switzerland, 1011
- University Hospitals
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Validated Informed Consent as documented by signature (Appendix Informed Consent Form)
- Depending on study arm:
- Good health (step 1 and 1 bis only) or
- Patients with at least 1 non calcified pulmonary nodule of at least 4 mm, whatever its texture (solid, sub-solid) and nature (benign, indeterminate or malignant), just discovered or in a follow-up context (step 2 only)
- Age ≥ 18 years
Exclusion Criteria:
- Previous or current disorder that might interfere with performance or safety of study procedures
- Age <18 years
- Any contraindication to MRI (pace makers, neuro-stimulators, some implantable devices, some metallic implants, claustrophobia)
- Any contraindication to a positive airway pressure therapy (claustrophobia, fracture of the skull, right heart failure), (step 1 bis)
- Children, adolescents and adults with incapacities
- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant
- Pregnant or breastfeeding women
Chronic obstructive pulmonary disease (COPD) or asthma with severe obstruction
- Severe obstructive patients (FEV1<50% of predicted value)
- Hypoxemia (SaO2<94% AA)
- History or physical signs of right heart failure
- History or physical signs of right or left cardiac failure
- History or physical signs of pulmonary hypertension
- History or physical signs of active coronary artery disease
- Pulmonary graft
- Immunocompromized patients
- Enrollment of the investigator, his/her family members, employees and other dependent persons
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NON_RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Step 1: Healthy volunteers
Experimental intervention: MRI data will be acquired with the use of HF-NIV (HF-NIV-MR). Control intervention: MRI data will be acquired without the use of HF-NIV, as a reference (MR). |
MRI data will be acquired with the use of HF-NIV.
MRI data will be acquired without the use of any device as a reference.
|
EXPERIMENTAL: Step 2: Patients (arm A)
Experimental intervention: MRI data will be acquired with the use of HF-NIV (HF-NIV-MR). Control intervention: MRI data will also be acquired without the use of HF-NIV, as a reference (MR). The clinically prescribed CT will be the gold standard. |
MRI data will be acquired with the use of HF-NIV.
MRI data will be acquired without the use of any device as a reference.
|
EXPERIMENTAL: Step 2: Patients (arm B)
Experimental intervention: PET/CT data will be acquired with the use of HF-NIV (HF-NIV-PET). MRI data will be acquired with the use of HF-NIV (HF-NIV-MR). PET/CT data will be acquired in inspiratory breath hold without the use of HF-NIV (PET/CT breath hold). Control intervention: Data from the clinically indicated PET/CT acquisition will be used as reference. MRI data will also be acquired without the use of HF-NIV, as a reference (MR). Histological data will be used when available. |
MRI data will be acquired with the use of HF-NIV.
MRI data will be acquired without the use of any device as a reference.
PET data will be acquired with the use of HF-NIV.
PET/CT data will be acquired in inspiratory breath hold without the use of HF-NIV.
|
EXPERIMENTAL: Step 1 bis: Healthy volunteers
Experimental intervention: MRI data will be acquired with the use of CPAP (CPAP-MR). Control intervention: MRI data will be acquired without the use of CPAP, as a reference (MR). |
MRI data will be acquired without the use of any device as a reference.
MRI data will be acquired with the use of CPAP.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Image quality, step 1: Healthy volunteers, sharpness of vessels
Time Frame: day 1
|
Sharpness of interfaces of vessels will be scored on a discrete scale as 1=blurred; 2=intermediate; 3=sharp.
This will determine the adequate choice of MR sequences and parameters.
|
day 1
|
Sensitivity for nodule detection, step 2: Patients (arm A)
Time Frame: day 1
|
Determine whether HF-NIV-MR allows a better detection (higher sensitivity) of the presence of pulmonary nodules compared with conventional MR.
CT will be used as gold standard.
|
day 1
|
Sensitivity for nodule characterization, step 2: Patients (arm B)
Time Frame: day 1
|
Determine whether sensitivity of the apparent diffusion coefficient (ADC) value obtained with HF-NIV-MR (diffusion sequence) to characterize nodules is higher than the sensitivity obtained with conventional MRI.
Histological data will be used as gold standard when available.
|
day 1
|
Assessment of CPAP-MR, step 1 bis: Healthy volunteers
Time Frame: day 1
|
Determine whether CPAP-MR has an additional value compared with MR.
Image quality of the CPAP-MR acquisition will be evaluated similarly to the methodology of step 1 and compared to the gold standard MR acquisition (free-breathing without any device).
|
day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Image quality, step 1: Healthy volunteers, sharpness of bronchi
Time Frame: day 1
|
Sharpness of interfaces of bronchi will be scored on a discrete scale as 1=blurred; 2=intermediate; 3=sharp.
|
day 1
|
Image quality, step 1: Healthy volunteers, sharpness of fissures
Time Frame: day 1
|
Sharpness of interfaces of fissures will be scored on a discrete scale as 1=blurred; 2=intermediate; 3=sharp.
|
day 1
|
Image quality, step 1: Healthy volunteers, visibility of vessels
Time Frame: day 1
|
Modified criteria of Ohno (Ohno et al.) will be used and vessels will be scored as follows 0=non visible; 1=depicted at a lobar level; 2=depicted at a segmental level; 3=depicted at a sub-segmental level; 4=depicted at a sub-sub segmental level; 5=depicted beyond the sub-subsegmental level.
|
day 1
|
Image quality, step 1: Healthy volunteers, visibility of bronchi
Time Frame: day 1
|
Modified criteria of Ohno (Ohno et al.) will be used and bronchi will be scored as follows 0=non visible; 1=depicted at a lobar level; 2=depicted at a segmental level; 3=depicted at a sub-segmental level; 4=depicted at a sub-sub segmental level; 5=depicted beyond the sub-subsegmental level.
|
day 1
|
Image quality, step 1: Healthy volunteers, visibility of fissures
Time Frame: day 1
|
Fissures will be scored as follows 0=non visible; 1=visible.
|
day 1
|
Nodule dimensions
Time Frame: day 1
|
The variable of interest will be the volumetry of each nodule detected which will be evaluated by using dedicated software. This will be compared with volumetric assessment by using CT performed less than 1 month before the MR examination, at best the same day. Two-Dimensional measurements (long axis, mean of the long and short diameter) will also be used, in accordance with usual recommendations [MacMahon et al.]. |
day 1
|
MR-PET fusion
Time Frame: day 1
|
Fusion of MR acquisitions and PET under HF-NIV should be obtained with a good accuracy.
The correspondence will be evaluated with a fiducial anatomical structures technique, as if acquisitions were done on a PET-MR scanner.
|
day 1
|
Correlation of diffusion MRI with metabolic activity
Time Frame: day 1
|
The correlation between ADC (diffusion coefficient) and metabolic activity in HF-NIV-PET/CT, will be compared to the one obtained without HF-NIV.
|
day 1
|
PET/CT stabilization assessment
Time Frame: day 1
|
The PET/CT image stabilization methods will compared and the best one will be determined (electronic respiratory-gating during the normal free-breathing PET/CT, a single short PET/CT apnea (<30 seconds) and the HF-NIV-PET/CT acquisition.
|
day 1
|
Correlation with ex-vivo nodule volume
Time Frame: day 1
|
When applicable, the volume of lesions measured on imaging studies will be compared to the volume measured ex-vivo following surgical resection.
|
day 1
|
Tolerance CPAP-MR, step 1 bis: Healthy volunteers
Time Frame: day 1
|
Subject subjective tolerance to CPAP-MR will be scored on a 5 points discrete scale as follows: 0=no additional discomfort, 1=minor discomfort, 2=moderate discomfort, 3=high discomfort, 4=extreme discomfort (same methodology as for steps 1 and 2).
|
day 1
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Catherine Beigelman-Aubry, MD, University Hospital Lausanne (CHUV), Radiology
Publications and helpful links
General Publications
- Beigelman-Aubry C, Peguret N, Stuber M, Delacoste J, Belmondo B, Lovis A, Simons J, Long O, Grant K, Berchier G, Rohner C, Bonanno G, Coppo S, Schwitter J, Ozsahin M, Qanadli S, Meuli R, Bourhis J. Chest-MRI under pulsatile flow ventilation: A new promising technique. PLoS One. 2017 Jun 12;12(6):e0178807. doi: 10.1371/journal.pone.0178807. eCollection 2017.
- Prior JO, Peguret N, Pomoni A, Pappon M, Zeverino M, Belmondo B, Lovis A, Ozsahin M, Vienne M, Bourhis J. Reduction of Respiratory Motion During PET/CT by Pulsatile-Flow Ventilation: A First Clinical Evaluation. J Nucl Med. 2016 Mar;57(3):416-9. doi: 10.2967/jnumed.115.163386. Epub 2015 Dec 3.
- MacMahon H, Naidich DP, Goo JM, Lee KS, Leung ANC, Mayo JR, Mehta AC, Ohno Y, Powell CA, Prokop M, Rubin GD, Schaefer-Prokop CM, Travis WD, Van Schil PE, Bankier AA. Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. Radiology. 2017 Jul;284(1):228-243. doi: 10.1148/radiol.2017161659. Epub 2017 Feb 23.
- Ohno Y, Koyama H, Yoshikawa T, Seki S, Takenaka D, Yui M, Lu A, Miyazaki M, Sugimura K. Pulmonary high-resolution ultrashort TE MR imaging: Comparison with thin-section standard- and low-dose computed tomography for the assessment of pulmonary parenchyma diseases. J Magn Reson Imaging. 2016 Feb;43(2):512-32. doi: 10.1002/jmri.25008. Epub 2015 Jul 30.
- Darcot E, Delacoste J, Dunet V, Dournes G, Rotzinger D, Bernasconi M, Vremaroiu P, Simons J, Long O, Rohner C, Ledoux JB, Stuber M, Lovis A, Beigelman-Aubry C. Lung MRI assessment with high-frequency noninvasive ventilation at 3 T. Magn Reson Imaging. 2020 Dec;74:64-73. doi: 10.1016/j.mri.2020.09.006. Epub 2020 Sep 6.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- HF-NIV-MR-PET
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms
-
GlaxoSmithKlineCompleted
-
Amphia HospitalRecruitingColonic Neoplasms MalignantNetherlands
-
Marquette General Health SystemUpper Michigan Brain Tumor CenterWithdrawnGlioma | MeningiomaUnited States
-
European Association for Endoscopic SurgeryWithdrawn
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedBrain Stem Neoplasms, Primary | Neoplasms, Brain StemUnited States
-
Moscow Clinical Scientific CenterRecruitingCecal Neoplasms | Colonic Neoplasms MalignantRussian Federation
-
GlaxoSmithKlineRecruitingNeoplasms, RectalUnited States, France, Italy, Japan, Spain, United Kingdom, Germany, Korea, Republic of, Canada, Netherlands
-
Russian Society of Colorectal SurgeonsRecruitingNeoplasms,ColorectalRussian Federation
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
Novartis PharmaceuticalsBayerCompletedColorectal Neoplasms | Rectal Neoplasms | Colonic NeoplasmsUnited States, Germany, Belgium, Canada, Spain, United Kingdom, Taiwan, France, Switzerland, Sweden, Portugal, New Zealand, Italy, Slovakia, Australia, Austria, Brazil, Hong Kong
Clinical Trials on HF-NIV-MR
-
Centre Hospitalier Universitaire VaudoisUnknownLung Diseases | Healthy Volunteer | Non-invasive Ventilation | High-frequency VentilationSwitzerland
-
Rennes University HospitalRecruitingChronic Obstructive Pulmonary Disease (COPD) | Obesity With a BMI Greater Than 30 | Acute Respiratory Distress in Adult Intensive CareFrance
-
VA Office of Research and DevelopmentCompleted
-
Yale UniversityNational Heart, Lung, and Blood Institute (NHLBI)Not yet recruiting
-
Texas Christian UniversityUnknownBody Weight ChangesUnited States
-
Population Health Research InstituteMcMaster University; Hamilton Health Sciences CorporationRecruiting
-
Abbott Medical DevicesCompleted
-
University Hospital, RouenUnknown
-
Vejle HospitalCompletedRespiratory Insufficiency | Acute Respiratory InsufficiencyDenmark
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Politecnico di MilanoCompletedPrematurity | Neonatal Respiratory Distress SyndromeItaly